Meningococcal Infections Completed Phase 2 Trials for Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)

Also known as: Infections, Meningococcal / Meningococcal Infection / Meningococcal disease / Unspecified meningococcal infection / Meningococcal infection, unspecified / Neisseria meningitidis infection NOS

IndicationStatusPhase
DBCOND0032814 (Meningococcal Infections)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00196976Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years OldPrevention
NCT02199691Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy AdolescentsPrevention
NCT01239043Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial VaccinationPrevention
NCT00721396Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization SchedulesPrevention
NCT02640404Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in VietnamPrevention
NCT01049035A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and ToddlersPrevention
NCT01442675Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra VaccinePrevention
NCT00269477Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®Prevention
NCT00127855Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) VaccinePrevention